Oracle Unveils New Version of Oracle Health Sciences ClearTrial Plan and Source Cloud Service
Cloud-Based Clinical Trial Operations Software Delivers Enhanced Planning, Sourcing, and Tracking Capabilities to Support Phase I Trials and Complex Multi-Arm Studies
Oracle Health Sciences today announced the availability of Oracle Health Sciences ClearTrial Plan and Source Cloud Service 5.0, the latest version of the cloud-based clinical trial operations solution that enables life sciences organizations to plan, source and track clinical projects and financial performance via a single, integrated platform.
The newest release now provides support for phase I trials, which when combined with existing capabilities, enables organizations to support a broad range of clinical trials – from initial safety screenings to complex testing and post-approval studies – in one scalable and flexible solution.
Further expanding the breadth and study types that sponsors and contract research organizations (CROs) can create and track, the latest release also provides support for multiple treatment arm studies – including complex cross over studies, in which different types and sequences of treatment courses are administered to various study groups.
Oracle Health Sciences ClearTrial Plan and Source is now delivered via the Oracle Health Sciences Cloud, providing users with improved performance, availability and fault tolerance. In addition, as a cloud-based solution, users will gain immediate access to ClearTrial’s enhanced functionality and improved user interface.
“We remain committed to evolving the breadth and depth of Oracle ClearTrial Plan and Source Cloud Service’s capabilities to provide life sciences organizations with the tools they need to conduct and track increasingly complex clinical trials across diverse geographies, outsourcers, therapeutic areas and trial phases,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “The new capabilities will allow life sciences organizations to gain a competitive edge in the marketplace while accelerating the process of bringing new therapies to market.”
Related Links
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
